⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13886363 | 0.81 | — | — | |
| SCHEMBL7826296 | 0.78 | TRPA1 (0.37) | — | |
| SCHEMBL3950975 | 0.77 | — | — | |
| SCHEMBL314782 | 0.75 | — | — | |
| SCHEMBL13400166 | 0.73 | GAA (0.43) | — | |
| SCHEMBL13156166 | 0.73 | GAA (0.38) | — | |
| SCHEMBL3714708 | 0.73 | — | — | |
| SCHEMBL3633544 | 0.73 | — | — | |
| SCHEMBL18718161 | 0.73 | — | — | |
| SCHEMBL10690402 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267142-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4185622-A1 | METALLOCENE COMPLEXES AND CATALYSTS MADE THEREFROM | Borealis AG (AT) | 2023-05-31 | — | — | EP | disclosed |
| EP-4185621-A1 | PROCESS FOR THE PREPARATION OF A MULTIMODAL POLYETHYLENE | Borealis AG (AT) | 2023-05-31 | — | — | EP | disclosed |
| WO-2022140647-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022018290-A1 | PROCESS FOR THE PREPARATION OF A MULTIMODAL POLYETHYLENE | BOREALIS AG (AT) | 2022-01-27 | — | — | WO | disclosed |
| EP-3852748-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Metacrine, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020061113-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| EP-3615533-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | Novartis AG (CH) | 2020-03-04 | — | — | EP | disclosed |
| EP-3532476-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-09-04 | — | — | EP | disclosed |
| EP-3507291-A1 | FUSED BICYCLIC SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| WO-2000042031-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-1999032106-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032111-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0741737-A1 | WATERSOLUBLE AZOLE ANTIFUNGALS | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995019983-A1 | WATERSOLUBLE AZOLE ANTIFUNGALS | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-07-27 | — | — | WO | disclosed |
| EP-0107366-A1 | Pyrrolidinone analogs and precursors | ELI LILLY AND COMPANY (US) | 1984-05-02 | — | — | EP | disclosed |
| EP-0010183-B1 | 3,3-BISFLUOROMETHYL-BUTAN-2-ONE AND PROCESS FOR ITS PREPARATION | BAYER AG (DE) | 1982-06-16 | — | — | EP | disclosed |
| US-4267381-A | SYNTHESIS OF FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-12 | — | — | US | disclosed |
| US-4255434-A | FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1981-03-10 | — | — | US | disclosed |
| EP-0010183-A1 | 3,3-bisfluoromethyl-butan-2-one and process for its preparation | BAYER AG (DE) | 1980-04-30 | — | — | EP | disclosed |